PARP1, poly(ADP-ribose) polymerase 1, 142

N. diseases: 565; N. variants: 23
Disease: Solid Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE The preclinical data and early clinical studies advocate the use of prexasertib in solid tumors both in monotherapy and in combination with other drugs (antimetabolites, PARP inhibitors and platinum-based chemotherapy). 31512029 2020
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE We conducted a phase 1/2 trial of the poly(ADP-ribose) polymerase 1/2 inhibitor talazoparib in combination with low-dose temozolomide (TMZ) to determine the dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). 31724813 2020
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma. 31676730 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Clinically, PARP1 Inhibitors have shown their potential in treating BRCAm breast and ovarian cancers and trials are going on for the treatment of other solid tumors like pancreatic, prostate, colorectal etc. as a single agent or in combination. 30684797 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with extensive-stage (ED) small cell lung cancer (SCLC) and other solid tumors. 30327308 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 GeneticVariation phenotype BEFREE The anticipating outcome of these trials may clarify the benefit of PARP inhibitors in management of various BRCA mutated solid tumors. 28699513 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE As the first PARP inhibitor approved for the treatment of advanced <i>BRCA</i>-mutated ovarian cancer, olaparib has proven to be effective in the treatment of several solid tumors. 30127642 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Recent studies have elucidated that PARP inhibitors and platinum agents may be effective to induce tumor regression in solid tumors bearing an unstable genome including pancreatic cancer. 26881472 2016
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). 26979391 2016
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. 25589624 2015
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. 25757679 2015